An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Jan 2019
At a glance
- Drugs Parsaclisib (Primary) ; Bendamustine; Obinutuzumab
- Indications Follicular lymphoma
- Focus Adverse reactions
- Acronyms CITADEL-102
- Sponsors Incyte Corporation
- 19 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 11 May 2017 Status changed from not yet recruiting to recruiting.